Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 6/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800514 | 0.81 | DAGLA (0.39) | DAGLAC3AR1FBP1SLC6A2SLC6A4 | |
| SCHEMBL12299227 | 0.81 | DAGLA (0.39) | DAGLAFBP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL800880 | 0.79 | DAGLA (0.39) | DAGLAFBP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13175023 | 0.79 | DAGLA (0.39) | DAGLAFBP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL805224 | 0.78 | DAGLA (0.38) | DAGLAHDAC1HDAC8HDAC6ALOX5AP | |
| SCHEMBL10045823 | 0.77 | C3AR1 (0.49) | C3AR1 | |
| SCHEMBL800520 | 0.77 | DAGLA (0.47) | DAGLASLC6A2SLC6A4SLC6A3HDAC1 | |
| SCHEMBL15214456 | 0.76 | DAGLA (0.39) | DAGLAFBP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7324378 | 0.76 | DAGLA (0.40) | DAGLAFBP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL801030 | 0.74 | HDAC1 (0.37) | DAGLAC3AR1FBP1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796300-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120238595-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2496704-A1 | THERAPEUTIC COMPOUNDS | Rutgers, The State University of New Jersey (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2011057126-A1 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238595-A1 | THERAPEUTIC COMPOUNDS | CCNY, MKI67, MCL1 | DAGLA 4607/4885C3AR1 1935/4885FBP1 4311/4885 |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, RECQL | DAGLA 4631/4885C3AR1 2510/4885FBP1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.